A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 107 participants.

Also called NCT02976467

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 107 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02976467
  • EudraCT 2016-002167-33
Other papers using this trial's data
  • Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial American heart journal, 2020-06 DOI, PubMed 32375104

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Czechia, Germany, Israel, Italy, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02976467. Randomized; quadruple masking; primary purpose treatment. Start 2016-12-30 (actual); primary completion 2018-07-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction
Acronym
CHIARA MIA 2
Intervention (Drug)
Fulacimstat (BAY1142524)
Intervention (Drug)
Placebo
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct02976467
Content hash
747825323ac6d6c474e8c313131bd19676bc28e3278a0aaa848fb857510a508f